DK1810676T3 - Levetiracetam formuleringer og fremgangsmåder til deres fremstilling - Google Patents

Levetiracetam formuleringer og fremgangsmåder til deres fremstilling

Info

Publication number
DK1810676T3
DK1810676T3 DK06251210T DK06251210T DK1810676T3 DK 1810676 T3 DK1810676 T3 DK 1810676T3 DK 06251210 T DK06251210 T DK 06251210T DK 06251210 T DK06251210 T DK 06251210T DK 1810676 T3 DK1810676 T3 DK 1810676T3
Authority
DK
Denmark
Prior art keywords
methods
preparation
levetiracetam
compositions
formulations
Prior art date
Application number
DK06251210T
Other languages
Danish (da)
English (en)
Inventor
Julia Hrakovsky
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1810676(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of DK1810676T3 publication Critical patent/DK1810676T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
DK06251210T 2006-01-24 2006-03-07 Levetiracetam formuleringer og fremgangsmåder til deres fremstilling DK1810676T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76210306P 2006-01-24 2006-01-24

Publications (1)

Publication Number Publication Date
DK1810676T3 true DK1810676T3 (da) 2009-02-09

Family

ID=36337638

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06251210T DK1810676T3 (da) 2006-01-24 2006-03-07 Levetiracetam formuleringer og fremgangsmåder til deres fremstilling

Country Status (13)

Country Link
US (1) US20070172521A1 (de)
EP (1) EP1810676B1 (de)
JP (1) JP2009524658A (de)
CN (1) CN101360493A (de)
AT (1) ATE413875T1 (de)
CA (1) CA2637925A1 (de)
DE (1) DE602006003617D1 (de)
DK (1) DK1810676T3 (de)
ES (1) ES2317452T3 (de)
IL (1) IL193024A0 (de)
PL (1) PL1810676T3 (de)
PT (1) PT1810676E (de)
WO (1) WO2007086891A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2380010T3 (es) 2007-10-16 2012-05-07 Pharmathen S.A. Composición farmacéutica mejorada que contiene un anticonvulsivante derivado de la pirrolidona y método para su preparación
WO2009069089A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Levetiracetam controlled release composition
WO2009135646A2 (en) * 2008-05-05 2009-11-12 Farmaprojects, Sa Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
CA2772275A1 (en) 2009-09-18 2011-03-24 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
CN101693017B (zh) * 2009-10-28 2012-06-06 北京赛科药业有限责任公司 左乙拉西坦的药物组合物及其制备方法
WO2011136751A2 (en) 2010-04-26 2011-11-03 Mahmut Bilgic Water soluble pharmaceutical composition
US8906949B2 (en) * 2010-05-21 2014-12-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of zolmitriptan and process for preparing the same
CN102379857B (zh) * 2011-05-30 2013-10-09 深圳信立泰药业股份有限公司 一种左乙拉西坦缓释药物组合物及其制备方法
CN102764254B (zh) * 2012-05-16 2016-09-07 深圳信立泰药业股份有限公司 一种左乙拉西坦药物组合物及其制备方法
JP6630229B2 (ja) * 2016-05-17 2020-01-15 エルメッド株式会社 レベチラセタム含有医薬組成物及びその製造方法
JP6422464B2 (ja) * 2016-05-19 2018-11-14 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
JP6326114B2 (ja) * 2016-11-01 2018-05-16 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514389A (en) * 1981-05-06 1985-04-30 Kyowa Chemical Industry Co. Ltd. Gastric antacid and method for controlling pH of gastric juice
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
DE60034815T2 (de) * 1999-12-01 2008-01-31 Ucb S.A. Ein pyrrolidinacetatderivat zur behandlung von chronischem oder neuropathischem schmerz
US20040116506A1 (en) * 2002-06-20 2004-06-17 Krusz John Claude Use of levetiracetam for treating or preventing acute headaches
CN1205938C (zh) * 2002-10-08 2005-06-15 深圳海王药业有限公司 具有改善哺乳动物微循环作用的产品
WO2004069796A2 (en) * 2003-02-03 2004-08-19 Teva Pharmaceutical Industries Ltd. Process for producing levetiracetam
TR200503397T1 (tr) * 2003-03-18 2007-03-21 Hetero Drugs Limited Levetirasetam'ın yeni kristal formları.
WO2005023763A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Process for the preparation of pure levetiracetam
PL1909764T3 (pl) * 2005-07-26 2015-03-31 Ucb Pharma Sa Kompozycje farmaceutyczne zawierające lewetyracetam i sposób ich wytwarzania

Also Published As

Publication number Publication date
IL193024A0 (en) 2009-02-11
ATE413875T1 (de) 2008-11-15
ES2317452T3 (es) 2009-04-16
CA2637925A1 (en) 2007-08-02
PT1810676E (pt) 2009-01-02
PL1810676T3 (pl) 2009-04-30
EP1810676A1 (de) 2007-07-25
WO2007086891A1 (en) 2007-08-02
EP1810676B1 (de) 2008-11-12
US20070172521A1 (en) 2007-07-26
CN101360493A (zh) 2009-02-04
JP2009524658A (ja) 2009-07-02
DE602006003617D1 (de) 2008-12-24

Similar Documents

Publication Publication Date Title
DK1810676T3 (da) Levetiracetam formuleringer og fremgangsmåder til deres fremstilling
NO20092611L (no) Krystallinsk faststoff Rasagilin base
DK1909764T3 (da) Farmaceutisk sammensætninger omfattende levetiracetam og fremgangsmåde til deres fremstilling
EP2535058A3 (de) Stabilisierung von Impfstoffen durch Lyophilisierung
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
UA112281C2 (uk) Стабільні інсектицидні композиції і способи їх отримання
WO2008049116A3 (en) Substituted indoles
DK1863812T3 (da) Dipeptidylpeptidase-IV-inhiberende forbindelser, fremgangsmåder til fremstilling af de samme og farmaceutiske sammensætninger indeholdende de samme som aktive midler
DK2460820T3 (da) PCV2-immunogene sammensætninger og fremgangsmåder til fremstilling af sådanne sammensætninger
DK3320919T3 (da) Multivalente pcv2-immunogeniske sammensætninger og fremgangsmåder til at fremstille sådanne sammensætninger
NO20084850L (no) MGLUR5 modulatorer I
DK1845954T3 (da) Oralt opløsende sammensætning af olanzapin og donepzil
DK3072507T3 (da) Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
EP1962838A4 (de) Farnesoid-x-rezeptor-agonisten
GEP20094784B (en) Sustained release pharmaceutical formulations
IL192108A (en) Triazulophyridines, pharmaceutical preparations and combinations containing them, process for their preparation and use as modulators of tyrosine kinase
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
WO2007106746A3 (en) Formulations for ecallantide
NO20084852L (no) MGLUR5 modulatorer V
DK1862158T3 (da) Farmaceutisk sammensætning til behandling af depression og fremgangsmåde til fremstilling deraf
ATE429906T1 (de) Trockene aripiprazolformulierungen
TW200738649A (en) Calcilytic compounds
BRPI0615135A2 (pt) composições de fármacos contendo matrizes de hipromelose de liberação controlada
UA95253C2 (ru) Соединения аналога камптотецина, способ их получения и фармацевтическая композиция, которая их содержит
DK1707564T3 (da) Indanyl-piperazinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse